Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07222397

2910 nm Erbium-Doped Fluoride Fiber Glass Laser for the Treatment of Advanced Perioral Lines and Wrinkles

The primary objective is to assess the efficacy, safety and satisfaction associated with the resurfacing treatment of perioral lines and wrinkles with the 2,910 nm mid-infrared Fiber Laser (UltraClear, Acclaro Medical) using both superficial epidermis ablation capabilities and the deep ablative and coagulative capabilities into the dermis for rejuvenation.

Participants will receive up to two treatments spaced 6-8 weeks apart, followed by a 1-month and 3-month follow-up visit during which the device will be evaluated for its effectiveness defined as improvement addressing perioral lines and wrinkles utilizing multiple scales completed by the investigator and blinded Independent Photographic Reviewers (IPRs). Additionally, safety, subjective overall aesthetic improvement and satisfaction will be monitored and tracked.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Photodamaged Skin Lines Skin Rhytids Wrinkles and Rhytides

Age range

50 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dermatology & Laser Surgery Center

Houston, Texas, 77030, United States

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Fitzpatrick skin type I-IV.
  • Male or female.
  • Subjects must be between 50 and 80 years of age.
  • Subjects must have the ability to receive up to two full face resurfacing laser treatment with specific focus on advanced perioral lines and wrinkles.
  • Subjects must read, understand, and sign the Informed Consent Form.
  • Subjects must be willing and able to comply with all follow-up visit requirements.
  • Subjects must agree to refrain from using cosmeceutical agents or topical agents during the study, except as directed by study investigator.
  • Subjects must be rated as Class II or Class III based on the Fitzpatrick Wrinkling and Degree of Elastosis Scale (FWS).
  • Subject identified as an appropriate candidate for study treatment based on principal investigator's opinion.
  • Subjects of childbearing potential have been on an acceptable form of contraception for 30 days prior to enrollment and agree to continue using throughout the course of the study.

Exclusion criteria

  • Subjects must not have active localized or systemic infections.
  • Subjects must not have a compromised ability for wound healing, such as: malnutrition, steroid use, history of collagen vascular disease (e.g., lupus, scleroderma, history of keloid scar formation), atrophic dermatitis or immunologic abnormalities such as vitiligo.
  • Subjects must not have had treatments with 5FU, diclofenac, imiquimod, steroids, retinoids, or PDT within 1-month prior to enrollment.
  • Subjects must not currently be taking Accutane or have taken Accutane within the last 1-month.
  • Subjects must not have a known allergy to lidocaine or epinephrine, topical or injectable products containing lidocaine or any numbing medications.
  • Subjects must not have had previous surgery and/or fat transfer in the treatment area within the last 6-months.
  • Subject must not have had injectable soft tissue fillers within the last 12 months in the treatment area.
  • Subject must not have had Poly-L-Lactic acid (PLLA) fillers within the last 2 years in the treatment area.
  • Subject must not have had permanent filler i.e., Polymethylmethacrylate (PMMA) in the treatment area.
  • Subjects must not have had neurotoxins within the last 3-months in the treatment area.
  • Subject must not have a personal history of any facial threads i.e., PDO (Polydioxanone), PLLA (Polylactic acid), PCL (Polycaprolactone) in the treatment area within the last 12 months.
  • Subject must not have had a pulse dye or vascular laser, non-ablative laser, microneedling, or energy-based device treatment in the treatment area within the last 3 months.
  • Subject must not have had an ablative laser treatment in the treatment area within the last 6 months.
  • Subjects must not have a personal history of malignant melanoma, keloid scars, generalized psoriasis or systemic diseases that would preclude the use of topical anesthesia.
  • Subject must not have active sunburn or excessively tanned skin.
  • Subjects must not be pregnant or breastfeeding, think they may be pregnant or are trying to get pregnant during the study.

Treatment and study plan

Laser Resurfacing

Device

Enrolled participants will be treated with the UltraClear 2,910nm mid-infrared laser using both superficial epidermal ablation and deep ablative and coagulative capabilities in the dermis for rejuvenation with a specific focus on perioral lines and wrinkles.

Other names: Ablative Fractional Laser Resurfacing, 2910 nm mid-infrared fiber laser

Primary outcomes

  1. Change in Fitzpatrick Wrinkling and Degree of Elastosis Scale (FWS)

    Time frame: From enrollment to the final follow-up visit (3-months following final treatment)

    Changes in perioral lines and wrinkles utilizing the Fitzpatrick Wrinkling and Degree of Elastosis Scale (FWS).

    A change of one point is considered a statistically significant change on a scale of 1-9, with one being the least noticeable wrinkles and nine being the deepest and most noticeable wrinkles.

    1 - 3 Fine wrinkles 4 - 6 Fine to moderate depth wrinkles, moderate number of lines 7 - 9 Fine to deep wrinkles, numerous lines, with or without redundant skin folds

  2. Percentage of Treatment Responders

    Time frame: From enrollment to the final follow-up visit (3-months following final treatment)

    o Comparison of the proportion of subjects (i.e., percentage of treatment responders) correctly identified by at least two out of three blinded Independent Photographic Reviewers (IPR).

  3. Change in Physician Global Aesthetic Improvement Scale (PGAIS)

    Time frame: From enrollment to the final follow-up visit (3-months following final treatment)

    Defined as a change in perioral lines and wrinkles utilizing the Physician Global Aesthetic Improvement Scale (PGAIS).

    The PGAIS is a five-point scale used by physicians to objectively rate the aesthetic outcome of a treatment by comparing a patient's pre-treatment and post-treatment appearance.

    The scoring is numerical (1-5), with a score of 3, 4, or 5 points being considered significant.

    • - Worse: The patient's aesthetic appearance has deteriorated compared to baseline
    • - No Change: There is no noticeable difference from the pre-treatment state.
    • - Improved: The physician notes a visible enhancement, but further treatment could still be beneficial
    • - Much Improved: There is a marked, clear aesthetic improvement
    • - Very Much Improved: An optimal cosmetic result has been achieved

Secondary outcomes

  1. Subject Self-Reported Improvements

    Time frame: From enrollment to the final follow-up visit (3-months following final treatment)

    The SGAIS is a measure of aesthetic improvement relative to baseline, pre-treatment condition. A meaningful change on the Subject Global Aesthetic Improvement Scale (SGAIS) is defined as an improvement of at least one grade, indicating that the subject perceives a beneficial change in their appearance. The SGAIS is a patient-reported outcome measure (PROM) that is completed by the patient/subject to assess their own perception of aesthetic improvement following treatment.

    The scale is reported with scores of 1-5.

    • - Worse: The subject perceives a deterioration in their appearance compared to before treatment
    • - No Change: There is no noticeable difference from the pre-treatment state
    • - Improved: The subject notes a visible aesthetic improvement
    • - Much Improved: The subject notes marked and definite aesthetic improvement
    • - Very Much Improved: The subject believes an optimal comment result has been achieved

Study contacts

Contact information is provided by the study sponsor or research team.

Leah Dickerson

CONTACT

[email protected]

Mary Dick, MD

CONTACT

[email protected]

713-900-3900

Sponsors and collaborators

Lead sponsor

FA Corporation

Industry

Registry information

Official study title

Evaluation of the 2910 nm Erbium-Doped Fluoride Fiber Glass Laser for the Treatment of Advanced Perioral Lines and Wrinkles

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Oct 29, 2025
Registry last updated
Oct 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.